Herpes zoster
Drug research and approvals for herpes zoster: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 53 studies of herpes zoster are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 53
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 53 recruiting on ClinicalTrials.gov ↗- Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)NCT07920172 · Phase 1 / Phase 2 · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · starts Nov 10, 2026
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsNCT07415252 · Phase 3 · SK Bioscience Co., Ltd. · starts Jul 4, 2026
- Subcutaneous Calcitonin in Acute Herpes ZosterNCT07655804 · Phase 3 · Tanta University · starts Jul 1, 2026
- Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) PainNCT07732556 · Not applicable · Tanta University · starts Jul 1, 2026
- Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveNCT07817108 · Phase 3 · Suzhou Abogen Biosciences Co., Ltd. · starts Jun 27, 2026
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine,…NCT07406360 · Phase 3 · GlaxoSmithKline · starts May 11, 2026
- A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population…NCT07502560 · Phase 4 · GlaxoSmithKline · starts Mar 31, 2026
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy…NCT07054099 · Phase 3 · GC Biopharma Corp · starts Mar 17, 2026
- Long-term Effectiveness of the Live Attenuated Herpes Zoster VaccineNCT07585370 · Not reported · Jiangsu Province Centers for Disease Control and Prevention · starts Mar 6, 2026
- Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine…NCT07534007 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Feb 24, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Sep 11, 2023 | A phase I/ii, observer-blind, randomised, placebo-controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an…HERPES SIMPLEX VIRUS (HSV)-TARGETED IMMUNOTHERAPY (GSK3943104A) | GSK | Ongoing |
| May 24, 2018 | "safety and immunogenicity of non-live, recombinant subunit herpes zoster vaccine in vzv-seronegative solid organ transplant recipients."SHINGRIX | UNIVERSITY HEALTH NETWORK | Pending |
| Mar 1, 2018 | Immunogenicity and safety study of gsk biologicals' herpes zoster vaccine gsk1437173a when co-administered with prevenar13 in adults aged 50 years and olderSHINGRIX | GSK | Closed |
| Apr 1, 2016 | A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (zoe-ltfu) of studies 110390 and 113077 (zoster-005/022) to assess the…HERPES ZOSTER SUBUNIT VACCINE (HZ/SU) (GSK1437173A) | GSK | Ongoing |
| Mar 11, 2016 | A phase IIIb, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of gsk biologicals' herpes zoster subunit…HERPES ZOSTER SUBUNIT VACCINE (GSK1437173A) | GSK | Ongoing |
| Nov 27, 2014 | A phase III, randomized, double blind multicenter study, to evaluate consistency, immunogenicity, safety and reactogenicity of 3 lots of gsk biologicals'…HERPES ZOSTER (HZ) VACCINE | GSK | Ongoing |
| Dec 10, 2013 | A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of gsk biologicals' herpes zoster vaccine gsk1437173a…HERPES ZOSTER (HZ) VACCINE (GSK1437173A) | GSK | Pending |
| Sep 6, 2013 | A phase III, randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety of gsk biological's herpes zoster vaccine gsk1437173a…HERPES ZOSTER (HZ) VACCINE | GSK | Ongoing |
| Apr 24, 2013 | "a phase III, randomised, observer-blind, placebo controlled, multicentre clinical study to assess the immunogenicity and safety of gask biologicals hz/su…HERPES ZOSTER (HZ) VACCINE | GSK | Ongoing |
| Apr 11, 2013 | "a phase III, non-randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety gsk biologicals' herpes zoster hz/su candidate…HERPES ZOSTER (HZ) VACCINE | GSK | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 9, 1995 | SorivudineTreatment of herpes zoster (shingles) in immunocompromised patients | Bristol-Myers Squibb | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Mar 21, 2018 | Shingrixherpes zoster vaccine (recombinant, adjuvanted) | GlaxoSmithKline Biologicals S.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA